NOVOLIN R Drug Profile

Summary for Tradename: NOVOLIN R

High Confidence Patents:	10
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for NOVOLIN R
Recent Clinical Trials:	See clinical trials for NOVOLIN R

See drug prices for NOVOLIN R

Recent Clinical Trials for NOVOLIN R

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Illinois at Chicago	Phase 2
State University of New York - Downstate Medical Center	Phase 4
University of California, San Francisco	N/A

See all NOVOLIN R clinical trials

Pharmacology for NOVOLIN R

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NOVOLIN R Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NOVOLIN R Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,462,535	2014-10-14	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,626,566	2014-03-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,693,027	2014-09-26	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,980,491	2017-07-03	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	6,074,372	2018-06-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NOVOLIN R Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	10,004,686	2033-06-12	Patent claims search
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	10,220,075	2036-05-19	Patent claims search
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	10,220,076	2035-05-15	Patent claims search
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	10,259,856	2035-04-14	Patent claims search
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	10,272,050	2035-10-14	Patent claims search

International Patents for NOVOLIN R

Country	Patent Number	Estimated Expiration
Australia	743662
Austria	123418
Canada	2119913
Austria	E249259
Norway	20025994

Market Dynamics and Financial Trajectory for NOVOLIN R

Last updated: April 11, 2026

What is NOVOLIN R?

NOVOLIN R is a recombinant human insulin developed by Novo Nordisk. It is a rapid-acting insulin used primarily for the management of blood glucose levels in people with diabetes. Approved globally, NOVOLIN R competes primarily with other rapid-acting insulins such as Humalog and Apidra.

Market Size and Growth Potential of Rapid-Acting Insulins

The global insulin market was valued at approximately USD 36.5 billion in 2022 and is projected to reach USD 55.2 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.2% over the period [1].

Key factors driving growth:

• Rising prevalence of diabetes: The International Diabetes Federation (IDF) reported 537 million adults with diabetes globally in 2021. This number is expected to increase to 643 million by 2030 [2].

• Shift toward insulin therapy: An increasing proportion of diabetic patients are transitioning from oral medications to injectable insulins and biosimilars.

• Aging population: Older adults with diabetes require ongoing insulin management, supporting sustained demand.

• Innovation: Development of faster-acting insulins (e.g., NOVOLIN R) influences market expansion.

Competitive Landscape

NOVOLIN R faces competition from several key products:

• Insulin Lispro (Humalog): Market leader with around 35% of rapid-acting insulin sales.

• Insulin Aspart (NovoRapid/Novolog): Holds roughly 25% of the market.

• Insulin Glulisine (Apidra): Represents a smaller segment.

Despite this, Novo Nordisk's established distribution channels and brand recognition afford NOVOLIN R a stable position.

Regulatory and Reimbursement Environment

Regulatory approvals span North America, Europe, and Asia-Pacific, with formalized reimbursement schemes varying:

• United States: Approved by the FDA in 2010; covered under Medicare and private insurance.

• European Union: CE marking achieved; reimbursement depends on national policies.

• Asia-Pacific: Growing acceptance, though reimbursement processes are heterogeneous.

Pricing strategies influence market penetration, with biosimilar competition pressuring prices downward.

Revenue and Financial Trajectory

Exact sales data for NOVOLIN R are proprietary; however, Novo Nordisk reports insulin segment revenues at approximately USD 23 billion in 2022, with rapid-acting insulins constituting a significant portion.

Projected factors affecting future revenues:

• Evolving biosimilar landscape: Entry of biosimilar versions could reduce prices and profit margins.

• R&D pipeline: Development of ultra-rapid insulins and insulin delivery technologies may impact sales.

• Market share shifts: As newer products gain approval, existing assets like NOVOLIN R could face decreased growth.

• Geographic expansion: Growing markets in Asia and Africa could improve revenues, contingent on regulatory acceptance.

Analyst estimates suggest that NOVOLIN R’s revenues could increase modestly over the next five years if market penetration remains stable and biosimilar competition is managed.

Pricing, Reimbursement, and Market Penetration

The average wholesale price (AWP) of NOVOLIN R varies by region:

Region	Approximate Price (per 10 mL vial)	Notes
United States	USD 80–USD 100	Reimbursed through insurance; manufacturer discounts apply
European Union	EUR 20–EUR 60	Price controls in place in some countries
Asia-Pacific	USD 30–USD 70	Price varies significantly by country

Reimbursement coverage is essential for widespread adoption. Payers increasingly evaluate biosimilar options, influencing demand.

Market Risks and Opportunities

Risks

• Biosimilar threat: Emerging biosimilars could drive prices lower and reduce profit margins.

• Regulatory delays: Stringent approval processes can slow market access.

• Price pressure: Healthcare systems’ cost containment measures limit pricing flexibility.

Opportunities

• Market expansion: Increasing diabetes prevalence in emerging economies creates growth opportunities.

• Formulation innovation: Developing ultra-rapid insulins and advanced delivery devices can capture new segments.

• Strategic partnerships: Collaborations with regional distributors facilitate market entry.

Key Takeaways

• NOVOLIN R is positioned within a growing insulin market, primarily driven by rising diabetes prevalence.

• Market growth is constrained by biosimilar competition and cost containment policies, especially in mature regions.

• Revenue projections indicate modest growth, with market share stability contingent on competitive positioning and geographic expansion.

• Pricing varies significantly across regions, affecting overall profitability and access.

• Innovation in formulation and delivery could enhance market share and extend product lifecycle.

FAQs

1. How does NOVOLIN R compare with alternative rapid-acting insulins?

   Its pharmacokinetic profile is similar, but Novo Nordisk emphasizes consistent absorption. Pricing and regional approval influence competitive positioning.

2. What impact could biosimilar insulins have on NOVOLIN R?

   Biosimilars typically reduce prices and profit margins but may also expand the total addressable market.

3. Are there upcoming formulations of NOVOLIN R?

   There are no publicly announced new formulations, but development efforts are ongoing in the industry for faster and more convenient insulins.

4. How does regulatory approval vary globally for NOVOLIN R?

   Approvals are widespread but may face delays in certain markets due to regulatory processes; reimbursement policies differ significantly.

5. What strategies can NOVO NORDISK implement to sustain NOVOLIN R sales?

   Focus on market expansion, technological innovation, and strategic collaborations can help sustain and grow sales despite biosimilar and pricing pressures.

---

References

[1] Grand View Research. (2023). Insulin Market Size, Share & Trends Analysis Report.
[2] International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edition.